Enliven 10-Q: Q3 Loss Widens to $27.7M, $884.4M Cash Funds Operations Into 2030
ELVN has more than doubled off its 52-week low of $14.785.
Summary
Enliven's Q3 2026 10-Q shows a $27.7M net loss on higher Phase 3 preparation spending, offset by $884.4M in cash and securities that management says funds operations into 2030.
Key Events · Earnings and Guidance · ELVN
-
Q3 Loss Widens on Phase 3 Prep
Net loss was $27.7M, or $0.36 per share, versus $20.1M a year earlier, as R&D rose to $28.0M from $18.2M.
-
Cash of $884.4M Funds Operations Into 2030
Cash and cash equivalents of $151.7M plus marketable securities of $732.7M totaled $884.4M at September 30, 2026, up from $462.6M at December 31, 2025.
-
June Offering and Option Exercises Drive Dilution
The June 2026 offering raised $460.0M gross ($432.6M net) on 10,533,334 shares at $37.50 plus 1,733,333 pre-funded warrants; 3,528,282 options were exercised for $42.7M, lifting shares outstanding to 73,557,369 from 59,440,045.
-
ATM Remains Untapped at $200M
No shares were sold under the Sales Agreement in the first nine months of 2026; $200.0M remains available, with 1,526,610 shares sold historically at a $26.20 weighted average for $38.6M net.
Analysis · ELVN · Life Sciences
The balance sheet is the story here: $884.4M in cash and securities after the June 2026 offering means Enliven does not need to raise money for years, removing the near-term financing risk that usually pressures a clinical-stage biotech's stock. The quarter's loss did grow as the company spends to launch the ENABLE-2 Phase 3 trial of relcobatinib. The trade-off is dilution already taken — shares outstanding rose to 73.6M from 59.4M at year-end 2025, driven by the $460.0M June offering and 3.5M option exercises.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELVN was trading at $44.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $14.79 to $62.32. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.